Access all of the content
We were delighted to speak with EASD President Prof. Stefano Del Prato (University of Pisa and University Hospital of Pisa) ahead of this year’s virtual meeting to hear how the meeting has been adapted to a virtual format.
1. How did you go about planning for virtual EASD?(00:05)
2. What key features are you introducing this year, especially considering the virtual setting?(06:00)
Disclosures: Prof. Del Prato has received research support from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme and served on the advisory board for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co., GlaxoSmithKline, Laboratoires Servier, Merck Sharp & Dohme, Mundipharma, Novartis Pharmaceuticals, Novo Nordisk, Sanofi and Takeda Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!